Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (9301)	3/20/1999 8:31:00 PM
From: Cacaito	Read Replies (1) \| Respond to of 17367

At the Xoma site and there is only reference to a treatment group and a placebo group. The protocol (post 6523) does not mentioned three arms, it does mentioned the stratification by Glasgow scores. My guess is that the company will try to insured good results and stratification plan for a prospective data collection is better for claiming subgroup analysis if overall data does not show it to begin with (awfully common repeated failure in the biotech industry and clinical research in general). My opinion: makes more sense to have the two as separate arms from the beginning and also for randomization purposes (and to have one single placebo group, some could argue for two placebo groups also stratified by severity scores. How could one compared treatment results with a non stratified placebo group? Better not to stratify at all to begin with. But, I will stop here following my own tail in circles. Regarding calling Ms Ellen Martin, I e-mailed in the past and requested a copy of the protocol. She said it is non public company information . The best info so far is post 6523, and still I could not figured out the legs.